Navigation Links
Statin Therapy Cuts Bad Cholesterol Unprecedented 70 Percent

Research conducted at the Methodist DeBakey Heart Center in Houston shows that a combination statin therapy lowers bad cholesterol by an unprecedented// 70 percent, and has the added benefit of reducing life-threatening inflammation that can lead to heart disease and stroke.

The results published this week in the American Journal of Cardiology, also show 46 percent reduction in C-reactive protein (CRP), a marker for inflammation, in patients treated with 40 mg of rosuvastatin and 10 mg ezetimibe.

“A seventy percent drop is the largest reduction in bad cholesterol ever seen in a statin clinical trial. Cardiologists have long recognized the challenge in helping high-risk patients reach their target cholesterol levels, to ultimately prevent heart attack and stroke,” said Dr. Christie Ballantyne, cardiologist at the Methodist DeBakey Heart Center and principal investigator for the study. “These results offer hope for these patients.”

In addition, inflammation can lead to serious complications such as heart attack and stroke, and high levels of CRP can predict these risks years before they actually occur, Ballantyne said. Physicians have long relied on blood cholesterol as a key indicator of cardiovascular risk, but recent research suggests that high risk patients who achieved a low CRP level combined with a low LDL-c level had the fewest cardiovascular events.

“The highly effective reductions in both LDL-c and CRP seen in the EXPLORER study provide a new opportunity for high-risk patients to achieve optimal reduction in both factors with combination therapy,” Ballantyne said.

Key findings from EXPLORER** study:

* Crestor and Zetia reduced mean LDL-C by an unprecedented 70%.

* Significantly (p<0.001) more patients achieved their NCEP ATP III LDL-C goal of <100 mg/dL (94% vs. 79%) at six weeks with Crestor and Zetia compared with Crestor monotherapy.

* Crestor and Zetia reduc ed CRP levels by 46% compared with 29% with Crestor monotherapy.

* Both CRESTOR monotherapy and CRESTOR combined with ezetimibe produced similar increases in HDL-C (“good” cholesterol) (8.5% vs. 10.8%).

* CRESTOR and ezetimibe were both well tolerated.

** EXPLORER (Examination of Potential Lipid modifying effects Of Rosuvastatin in combination with Ezetimibe versus Rosuvastatin alone) was a 12-week, randomized trial of 469 patients with LDL-C 160-<250 mg/dL (4.1-<6.5 mmol/L) and coronary heart disease (CHD) or CHD risk equivalent designed to evaluate whether adding ezetimibe to CRESTOR would enable more patients with severely high cholesterol to achieve guideline lipid goals compared with CRESTOR monotherapy. Patients participated in a six-week dietary lead-in followed by six weeks of randomized treatment with rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg.

Source-NewswiseBR>SRM
'"/>




Related medicine news :

1. Statins reduce heart attacks
2. Statins reduce risks for angioplasty patients
3. Statins Found To Be Helpful For Patients With Arthritis
4. Long-Term Benefits Of Statins Questioned
5. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
6. Use of Statin can help in recovery from stroke
7. Statins Not Effective In Treating Calcific Aortic Stenosis
8. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
9. The Effects of Statins Questioned
10. Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well
11. Study Finds No Link Between Statins And Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... "ProBrand Flip ... and all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand ... easy to use drop zones. Editors can select from a variety of flip book ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... to present at the International Probiotic Association’s Washington DC workshop on November 2nd. ... to engage in dialog regarding probiotic dietary supplement regulations. , Dr. Leyer ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... because of a higher risk of serious health problems, such as cardiovascular illness, ... Dr. Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  Regulus ... biopharmaceutical company leading the discovery and development of ... drug development candidates at its R&D day, held ... first candidate, RGLS5040, is an anti-miR targeting microRNA-27 ... second candidate, RGLS4326, is an anti-miR targeting microRNA-17 ...
(Date:12/6/2016)... - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... in the use of cannabinoids for the treatment ... 2015 InMed initiated its COPD program using its ... potential active compounds that can be useful for ... assays using human lung fibroblasts (HFL-1 cell line), ...
Breaking Medicine Technology: